Rhythm Pharmaceuticals (MEX:RYTM) Inventories, Finished Goods: MXN383 Mil (As of Mar. 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
55 GF Score
Price MXN1,866.76
GF Value MXN1,817.22
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Inventories, Finished Goods?

Rhythm Pharmaceuticals MEX:RYTM 55 Inventories, Finished Goods is MXN383 Mil as of Mar. 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 55/100 and a GF Value™ of MXN1,817.22. The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's quarterly finished goods increased from Sep. 2025 (MXN267 Mil) to Dec. 2025 (MXN313 Mil) and increased from Dec. 2025 (MXN313 Mil) to Mar. 2026 (MXN383 Mil).

Rhythm Pharmaceuticals's annual finished goods increased from Dec. 2023 (MXN49 Mil) to Dec. 2024 (MXN223 Mil) and increased from Dec. 2024 (MXN223 Mil) to Dec. 2025 (MXN313 Mil).

Rhythm Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Inventories, Finished Goods Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 3.80 49.14 223.47 312.89

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 257.77 256.60 266.74 312.89 382.60
MEX:RYTM
55GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN383 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Inventories, Finished Goods of MXN383 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Inventories, Finished Goods too high?
Rhythm Pharmaceuticals' current Inventories, Finished Goods is MXN383 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Inventories, Finished Goods compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Inventories, Finished Goods of MXN383 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Inventories, Finished Goods is MXN383 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Inventories, Finished Goods of MXN383 Mil. The stock's GF Value™ is MXN1,817.22, compared to a current price of MXN1,866.76 — trading 2.7% above its estimated fair value. The current Inventories, Finished Goods is MXN383 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Inventories, Finished Goods is MXN383 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,866.76 is trading 2.7% above its estimated GF Value™ of MXN1,817.22.

Key valuation signals for MEX:RYTM:

  • Inventories, Finished Goods: MXN383 Mil
  • GF Value™: MXN1,817.22 vs. price of MXN1,866.76 (2.7% above fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
55GF Score

Get the complete analysis for MEX:RYTM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,817.22
GF Value